IP Library Granted Patent US 9,777,281
Granted Patent B2
US 9,777,281 · App. 14/832,434 · Granted Oct 3, 2017

Methods and compositions for regulation of transgene expression

Inventor: Edward J. Rebar (San Francisco, CA)
Assignee: Sangamo Therapeutics, Inc.
C12N15/62C07K14/00C12N9/22C12N9/96C12N15/85C07K2319/81C12N2799/025
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,777,281
App. No.
14/832,434
Granted
Oct 3, 2017
Kind
B2
Abstract

Nucleases and methods of using these nucleases for expressing a transgene from a safe harbor locus in a secretory tissue, and clones and animals derived therefrom.

Claims (13)

1. A polynucleotide encoding a non-naturally occurring fusion protein comprising

(i) a Transcription Activator Like Effector (TALE) DNA binding domain that binds to an endogenous albumin gene, wherein the TALE DNA binding protein comprises a plurality of TALE repeat units, each TALE repeat unit comprising an amino acid Repeat Variable Diresidue (RVD) that binds to a nucleotide in a target sequence in an endogenous albumin gene, wherein the TALE DNA binding domain comprises a +17 or +63C-terminal truncation and

(ii) a cleavage domain,

wherein the non-naturally occurring fusion protein cleaves the endogenous albumin gene.

2. An isolated cell comprising one or more polynucleotides according to claim 1 .

3. The isolated cell of claim 2 , wherein the cell is a stem cell.

4. The cell of claim 3 , wherein the stem cell is selected from the group consisting of an embryonic stem cell (ESC), an induced pluripotent stem cell (iPSC), a hepatic stem cell and a liver stem cell.

5. A kit comprising the polynucleotide according to claim 1 .

6. A method of cleaving an endogenous albumin gene in a cell, the method comprising:

introducing, into the cell, one or more polynucleotides according to claim 1 , under conditions such that the one or more fusion proteins—are expressed and the endogenous albumin gene is cleaved.

7. The method of claim 6 , wherein the one or more polynucleotides comprise mRNA.

8. The method of claim 6 , wherein the one or more polynucleotides are included in one or more expression vectors.

9. The method of claim 6 , wherein the cell is a liver cell.

Assignments (1)
CHANGE OF NAME Recorded Aug 17, 2017
From: SANGAMO BIOSCIENCES, INC.
To: SANGAMO THERAPEUTICS, INC.
Reel/Frame 043594/0152 →
Continuity (5)
Division 13624217 · Sep 21, 2012
Provisional Application 61537349 · Sep 21, 2011
Provisional Application 61560506 · Nov 16, 2011
Provisional Application 61670490 · Jul 11, 2012
Related Publication 20150344893A1 · Dec 3, 2015